Growth hormone replacement therapy in growth hormone deficient children and adults: Effects on hemochrome

S. Bergamaschi, C. Giavoli, E. Ferrante, A. Lania, R. Rusconi, A. Spada, Paolo Beck-Peccoz

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Several lines of evidence have suggested a role of the GH/IGF-I axis in the regulation of hemochrome. Many studies have been carried out in GH deficient children and adults about this topic, reporting predominantly a positive effect of recombinant human GH (rhGH) on red series, with no action on serum leucocytes and platelets counts. The aim of this study was to assess the impact of GH deficiency (GHD) and of rhGH replacement on blood cells count in 17 pre-pubertal children with idiopathic isolated GHD (11 males and 6 females, aged 9.1±0.8 yr) and in 18 patients with adult-onset GHD (12 males and 6 females, aged 47.9±3.0 yr). Evaluation of absolute and SD score (SDS) values of red blood cells, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets and white blood cells was performed at baseline and after 12 months of rhGH treatment (0.045±0.001 mg/kg bw/day and 4.2±0.5 μg/kg bw/day for children and adults, respectively). At baseline, all patients showed low IGF-I levels. Effectiveness of rhGH therapy was documented by significant increase in height SDS, height velocity and serum IGF-I levels in children. In adults, adequacy of rhGH was demonstrated by significant increase in serum IGF-I and significant decrease in body fat. At baseline, about 25% of patients (4 of 17 children and 4 of 18 adults) showed normochromic normocytic anemia, while the other indices were normal. In 7 of the 8 anemic patients, normal levels of hemoglobin were restored on rhGH, while no change in all the other indices was observed. In conclusion, rhGH therapy at physiological doses has no effect on erythropoiesis in GHD children and adults with normal blood cells count, while in patients with normochromic normocytic anemia rhGH is able to restore normal hemoglobin levels.

Original languageEnglish
Pages (from-to)399-404
Number of pages6
JournalJournal of Endocrinological Investigation
Volume29
Issue number5
Publication statusPublished - May 2006

Fingerprint

Hormone Replacement Therapy
Growth Hormone
Insulin-Like Growth Factor I
Erythrocyte Indices
Hemoglobins
Blood Cell Count
Anemia
Serum
Pituitary Dwarfism
Erythropoiesis
Platelet Count
Leukocyte Count
Hematocrit
Adipose Tissue
Leukocytes
Therapeutics
Blood Platelets
Erythrocytes

Keywords

  • Children
  • Growth hormone
  • Hemochrome

ASJC Scopus subject areas

  • Endocrinology

Cite this

Growth hormone replacement therapy in growth hormone deficient children and adults : Effects on hemochrome. / Bergamaschi, S.; Giavoli, C.; Ferrante, E.; Lania, A.; Rusconi, R.; Spada, A.; Beck-Peccoz, Paolo.

In: Journal of Endocrinological Investigation, Vol. 29, No. 5, 05.2006, p. 399-404.

Research output: Contribution to journalArticle

Bergamaschi, S. ; Giavoli, C. ; Ferrante, E. ; Lania, A. ; Rusconi, R. ; Spada, A. ; Beck-Peccoz, Paolo. / Growth hormone replacement therapy in growth hormone deficient children and adults : Effects on hemochrome. In: Journal of Endocrinological Investigation. 2006 ; Vol. 29, No. 5. pp. 399-404.
@article{63edcad79a034843b612ace9db6c9d58,
title = "Growth hormone replacement therapy in growth hormone deficient children and adults: Effects on hemochrome",
abstract = "Several lines of evidence have suggested a role of the GH/IGF-I axis in the regulation of hemochrome. Many studies have been carried out in GH deficient children and adults about this topic, reporting predominantly a positive effect of recombinant human GH (rhGH) on red series, with no action on serum leucocytes and platelets counts. The aim of this study was to assess the impact of GH deficiency (GHD) and of rhGH replacement on blood cells count in 17 pre-pubertal children with idiopathic isolated GHD (11 males and 6 females, aged 9.1±0.8 yr) and in 18 patients with adult-onset GHD (12 males and 6 females, aged 47.9±3.0 yr). Evaluation of absolute and SD score (SDS) values of red blood cells, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets and white blood cells was performed at baseline and after 12 months of rhGH treatment (0.045±0.001 mg/kg bw/day and 4.2±0.5 μg/kg bw/day for children and adults, respectively). At baseline, all patients showed low IGF-I levels. Effectiveness of rhGH therapy was documented by significant increase in height SDS, height velocity and serum IGF-I levels in children. In adults, adequacy of rhGH was demonstrated by significant increase in serum IGF-I and significant decrease in body fat. At baseline, about 25{\%} of patients (4 of 17 children and 4 of 18 adults) showed normochromic normocytic anemia, while the other indices were normal. In 7 of the 8 anemic patients, normal levels of hemoglobin were restored on rhGH, while no change in all the other indices was observed. In conclusion, rhGH therapy at physiological doses has no effect on erythropoiesis in GHD children and adults with normal blood cells count, while in patients with normochromic normocytic anemia rhGH is able to restore normal hemoglobin levels.",
keywords = "Children, Growth hormone, Hemochrome",
author = "S. Bergamaschi and C. Giavoli and E. Ferrante and A. Lania and R. Rusconi and A. Spada and Paolo Beck-Peccoz",
year = "2006",
month = "5",
language = "English",
volume = "29",
pages = "399--404",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "5",

}

TY - JOUR

T1 - Growth hormone replacement therapy in growth hormone deficient children and adults

T2 - Effects on hemochrome

AU - Bergamaschi, S.

AU - Giavoli, C.

AU - Ferrante, E.

AU - Lania, A.

AU - Rusconi, R.

AU - Spada, A.

AU - Beck-Peccoz, Paolo

PY - 2006/5

Y1 - 2006/5

N2 - Several lines of evidence have suggested a role of the GH/IGF-I axis in the regulation of hemochrome. Many studies have been carried out in GH deficient children and adults about this topic, reporting predominantly a positive effect of recombinant human GH (rhGH) on red series, with no action on serum leucocytes and platelets counts. The aim of this study was to assess the impact of GH deficiency (GHD) and of rhGH replacement on blood cells count in 17 pre-pubertal children with idiopathic isolated GHD (11 males and 6 females, aged 9.1±0.8 yr) and in 18 patients with adult-onset GHD (12 males and 6 females, aged 47.9±3.0 yr). Evaluation of absolute and SD score (SDS) values of red blood cells, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets and white blood cells was performed at baseline and after 12 months of rhGH treatment (0.045±0.001 mg/kg bw/day and 4.2±0.5 μg/kg bw/day for children and adults, respectively). At baseline, all patients showed low IGF-I levels. Effectiveness of rhGH therapy was documented by significant increase in height SDS, height velocity and serum IGF-I levels in children. In adults, adequacy of rhGH was demonstrated by significant increase in serum IGF-I and significant decrease in body fat. At baseline, about 25% of patients (4 of 17 children and 4 of 18 adults) showed normochromic normocytic anemia, while the other indices were normal. In 7 of the 8 anemic patients, normal levels of hemoglobin were restored on rhGH, while no change in all the other indices was observed. In conclusion, rhGH therapy at physiological doses has no effect on erythropoiesis in GHD children and adults with normal blood cells count, while in patients with normochromic normocytic anemia rhGH is able to restore normal hemoglobin levels.

AB - Several lines of evidence have suggested a role of the GH/IGF-I axis in the regulation of hemochrome. Many studies have been carried out in GH deficient children and adults about this topic, reporting predominantly a positive effect of recombinant human GH (rhGH) on red series, with no action on serum leucocytes and platelets counts. The aim of this study was to assess the impact of GH deficiency (GHD) and of rhGH replacement on blood cells count in 17 pre-pubertal children with idiopathic isolated GHD (11 males and 6 females, aged 9.1±0.8 yr) and in 18 patients with adult-onset GHD (12 males and 6 females, aged 47.9±3.0 yr). Evaluation of absolute and SD score (SDS) values of red blood cells, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets and white blood cells was performed at baseline and after 12 months of rhGH treatment (0.045±0.001 mg/kg bw/day and 4.2±0.5 μg/kg bw/day for children and adults, respectively). At baseline, all patients showed low IGF-I levels. Effectiveness of rhGH therapy was documented by significant increase in height SDS, height velocity and serum IGF-I levels in children. In adults, adequacy of rhGH was demonstrated by significant increase in serum IGF-I and significant decrease in body fat. At baseline, about 25% of patients (4 of 17 children and 4 of 18 adults) showed normochromic normocytic anemia, while the other indices were normal. In 7 of the 8 anemic patients, normal levels of hemoglobin were restored on rhGH, while no change in all the other indices was observed. In conclusion, rhGH therapy at physiological doses has no effect on erythropoiesis in GHD children and adults with normal blood cells count, while in patients with normochromic normocytic anemia rhGH is able to restore normal hemoglobin levels.

KW - Children

KW - Growth hormone

KW - Hemochrome

UR - http://www.scopus.com/inward/record.url?scp=33745874078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745874078&partnerID=8YFLogxK

M3 - Article

C2 - 16794362

AN - SCOPUS:33745874078

VL - 29

SP - 399

EP - 404

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 5

ER -